

Attorney Docket No.: 5709.200-US

PATENT

#12/3
NB
02/07/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al.

Application No.: 09/441,313

Group Art Unit: 1652

Filed: November 16, 1999

Examiner: Hutson, R

For: Alpha-amylase variants

AMENDMENT AND RESPONSE

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Before the above-captioned application, entry of the following amendment is respectfully requested (a marked up version pursuant to 37 C.F.R. 1.21 is attached hereto):

IN THE SPECIFICATION:

On page 5, the paragraph of lines 4-7, has been amended as follows:

8¹ --According to this nomenclature, for instance the substitution of alanine for asparagine in position 30 is shown as:

Asn30Ala or N30A--

On page 5, the paragraph of lines 21-27, has been amended as follows:

8² --Multiple mutations are separated by plus signs, i.e.:


Ala30Asp + Glu34Ser or A30N+E34S

representing mutations in positions 30 and 34 substituting alanine and glutamic acid for asparagine and serine, respectively. Multiple mutations may also be separated as follows, i.e., meaning the same as the plus sign:

Asp30Ala/Ser34Glu or N30A/S34E--

On page 13, please amend the paragraph of lines 6-13 as follows:

RECEIVED
FEB 04 2002
TECH CENTER 1600/2900



Attorney Docket No.: 5709.200-U.S.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventive Application of: Svendsen et al.

Confirmation No: 4161

Serial No.: 09/441,313

Group Art Unit: 1652

Filed: November 16, 1999

Examiner: R. Hutson

For: α -amylase variants

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


1. Amendment Fee Transmittal (in duplicate)
2. Amendment and Marked Up Version pursuant to 37 C.F.R. 1.21

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231


on: November 5, 2001.

Kelley O'Patry
(name of person mailing paper)


(signature of person mailing paper)

CP 1652
PATENT

RECEIVED
FEB 04 2002
TECH CENTER 1600/2900



Attorney Docket No.: 5709.200-U.S.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor Application of: Svendsen et al.

Confirmation No: 4161

Serial No.: 09/441,313

Group Art Unit: 1652

Filed: November 16, 1999

Examiner: R. Hutson

For: α -amylase variants

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed May 4, 2001.


It is respectfully requested that the time for response to the Office Action be extended for a period of 3 months from August 4, 2001 to November 4, 2001. The required fee for the extension is estimated to be \$890.

No additional claims fee is required.

Please charge the required extension and claims fees, estimated to be \$890, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 5, 2001



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

01/28/2002 SZEWDIE1 00000115 501701 09441313

01 FC:117 920.00 CH

RECEIVED
FEB 04 2002
TECH CENTER 1600/2900